# A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer

> **NCT01337518** · PHASE1 · SUSPENDED · sponsor: **Enzon Pharmaceuticals, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Prostatic Neoplasm

## Interventions

- **DRUG:** EZN-4176

## Key facts

- **NCT ID:** NCT01337518
- **Lead sponsor:** Enzon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2011-03
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 150 (ESTIMATED)
- **Why stopped:** Reassessment of strategic direction
- **Last updated:** 2012-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01337518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01337518, "A Phase 1a/1b Study to Evaluate the Safety of EZN-4176, in Adult Patients With Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01337518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*